Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07643896
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk AssessmentBillionToOne Inc.Recruiting
NCT07643896Recruiting
—
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Condit...BillionToOne Inc.
NCT07644455
Percutaneous Biopsy After Neoadjuvant Chemotherapy.Instituto do Cancer do Estado de São PauloNot Yet RecruitingNot Applicable
NCT07644455Not Yet Recruiting
Not Applicable
Percutaneous Biopsy After Neoadjuvant Chemotherapy.Instituto do Cancer do Es...
NCT07645599
Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft FunctionRoderick TanNot Yet Recruiting
NCT07645599Not Yet Recruiting
—
Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Functio...Roderick Tan
NCT07644819
Preoperative Outreach to Improve Surgical AttendanceUniversity of California, San FranciscoNot Yet RecruitingNot Applicable
NCT07644819Not Yet Recruiting
Not Applicable
Preoperative Outreach to Improve Surgical AttendanceUniversity of California,...
NCT07644598
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate CancerGeorgetown UniversityNot Yet RecruitingPhase 2
NCT07644598Not Yet Recruiting
Phase 2
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensificati...Georgetown University
NCT07645976
Home Environmental Risks and Caregiver AwarenessMarmara University Pendik Training and Research HospitalCompleted
NCT07644429
Biomechanical Characterisation of 3D Printed Comfort InsolesUniversity of PecsActive Not RecruitingNot Applicable
NCT07644429Active Not Recruiting
Not Applicable
Biomechanical Characterisation of 3D Printed Comfort InsolesUniversity of Pecs
NCT07644871
A 4-week Study Investigating Two Targeted Brightening Serum (A and B) Versus 4% Hydroquinone in Women With Mild to Severe Full-face HyperpigmentationRevision SkincareCompletedNot Applicable
NCT07644871Completed
Not Applicable
A 4-week Study Investigating Two Targeted Brightening Serum (A and B) Versus 4%...Revision Skincare
NCT07643831
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast CancerGenentech, Inc.Unknown
NCT07643831Unknown
—
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2-...Genentech, Inc.
NCT07646418
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International UniversityRecruitingNot Applicable
NCT07646418Recruiting
Not Applicable
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International Univ...
NCT07645196
Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With DysmenorrheaVrije Universiteit BrusselNot Yet RecruitingNot Applicable
NCT07645196Not Yet Recruiting
Not Applicable
Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With Dys...Vrije Universiteit Brusse...
NCT07645690
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell CarcinomaChinese PLA General HospitalRecruitingEarly Phase 1
NCT07645690Recruiting
Early Phase 1
The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Meta...Chinese PLA General Hospi...
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerVerastem, Inc.RecruitingPhase 2
NCT07644559Recruiting
Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerVerastem, Inc.
NCT07646028
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLCNot Yet RecruitingPhase 1
NCT07646028Not Yet Recruiting
Phase 1
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLC
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07645326
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Georgetown UniversityNot Yet RecruitingPhase 2
NCT07645326Not Yet Recruiting
Phase 2
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Georgetown University
NCT07644936
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisNot Yet Recruiting
NCT07644936Not Yet Recruiting
—
Molecular Characterization of Autoimmune Hepatitis: A Lipidomic ApproachAzienda Ospedaliera Speci...
NCT07645846
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital, Sun Yat-Sen UniversityNot Yet RecruitingPhase 2
NCT07645846Not Yet Recruiting
Phase 2
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting6 (30%)
Completed2 (10%)
Active, not recruiting1 (5%)
Unknown1 (5%)
not_applicable6 (30%)
Not Specified5 (25%)
Phase 25 (25%)
Phase 13 (15%)
Early Phase 11 (5%)